GW Pharmaceuticals Plc (GWPH)

102.40
1.20 1.10
NASDAQ : Health Technology
Prev Close 103.56
Open 103.01
Day Low/High 101.61 / 104.96
52 Wk Low/High 90.14 / 196.00
Volume 198.88K
Avg Volume 696.30K
Exchange NASDAQ
Shares Outstanding 30.72M
Market Cap 3.15B
EPS -9.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

The Market Is Still in Reset Mode, but Indices Are Holding Up

The Market Is Still in Reset Mode, but Indices Are Holding Up

Many stocks need rest and small-cap earnings season is rocky, but that doesn't mean the indices are going to see significant downside.

Only the Prices Have Changed: Cramer's 'Mad Money' Recap (Thursday 10/31/19)

Only the Prices Have Changed: Cramer's 'Mad Money' Recap (Thursday 10/31/19)

Jim Cramer says he's still bullish, and this pullback is a Halloween Sale that investors should see as a buying opportunity in disguise.

Slack, Xilinx, Nvidia: 'Mad Money' Lightning Round

Slack, Xilinx, Nvidia: 'Mad Money' Lightning Round

Jim Cramer takes a look at Slack, Xilinx, Nvidia, Advanced Micro Devices, Occidental Petroleum, OneSpan, Covanta and more.

You Can't Fight Progress: Cramer's 'Mad Money' Recap (Monday 10/7/19)

You Can't Fight Progress: Cramer's 'Mad Money' Recap (Monday 10/7/19)

Jim Cramer has a lot of faith in the progress of American business and, he says, it won't stand still for naysayers and an industry with a bias toward indexing.

Walt Disney Co., Spotify, Carnival: 'Mad Money' Lightning Round

Walt Disney Co., Spotify, Carnival: 'Mad Money' Lightning Round

Jim Cramer weighs in on Walt Disney Co., Spotify, Carnival, New Relic, Leidos, GW Pharmaceuticals and more.

Jim Cramer: Let's Wait for Full Story on Promising GW Pharma Drug

Jim Cramer: Let's Wait for Full Story on Promising GW Pharma Drug

After a negative report on GW's epilepsy treatment, the analyst refused to explain the results with me, bringing more questions than answers about its conclusions.

Jim Cramer: Let's Wait for Full Story on Promising GW Pharma Drug

Jim Cramer: Let's Wait for Full Story on Promising GW Pharma Drug

After a negative report on GW's epilepsy treatment, the analyst refused to explain the results with me, bringing more questions than answers about its conclusions.

GW Pharmaceuticals Could Fall Another 30% From Here

GW Pharmaceuticals Could Fall Another 30% From Here

Shares of the cannabinoid prescription medicine company look to be in a weak state.

Partisan Acrimony Per Share: Cramer's 'Mad Money' Recap (Tuesday 9/24/19)

Partisan Acrimony Per Share: Cramer's 'Mad Money' Recap (Tuesday 9/24/19)

Jim Cramer says we have another metric to judge stocks (partisan acrimony per share) and an impeachment sideshow to distract us from investor fundamentals.

How to Trade GW Pharma as Stock Eases

How to Trade GW Pharma as Stock Eases

GW Pharma stock does not look healthy. Here are the must-know levels on the cannabis company now.

GW Pharma Receives EU Approval for CBD-Based Seizure Treatment

GW Pharma Receives EU Approval for CBD-Based Seizure Treatment

European Union officials approve the company's CBD-based seizure treatment candidate.

Recession and Disbelief: Cramer's 'Mad Money' Recap (Thursday 9/5/19)

Recession and Disbelief: Cramer's 'Mad Money' Recap (Thursday 9/5/19)

Jim Cramer says we got good news on trade talks, and strong economic and employment data, all of which add up to a rally that defies recession talk.

Beyond Meat, Yum! Brands, Netflix: 'Mad Money' Lightning Round

Beyond Meat, Yum! Brands, Netflix: 'Mad Money' Lightning Round

Jim Cramer weighs in on Beyond Meat, Yum! Brands, Netflix, Starwood Property Trust, and GW Pharmaceuticals.

CBD-Laced Foods Could Be Technically Illegal, But the FDA Might Soon Change That

CBD-Laced Foods Could Be Technically Illegal, But the FDA Might Soon Change That

Agency has the authority to carve out an exception to existing laws.

The Rally in GW Pharmaceuticals Should Continue - Here's How I'd Play It

The Rally in GW Pharmaceuticals Should Continue - Here's How I'd Play It

Let's see how the charts of GWPH are shaping up.

GW Pharma Surges on Marijuana-Based Epilepsy Drug Sales, Analyst Upgrades

GW Pharma Surges on Marijuana-Based Epilepsy Drug Sales, Analyst Upgrades

Shares of GW Pharmaceuticals surge following soaring sales of its marijuana-derived epilepsy drug that prompts two analysts to raise their stock-price targets.

Cannabis Company Sundial Growers Wilts in Public Debut

Cannabis Company Sundial Growers Wilts in Public Debut

The shares slumped amid concern about another Canadian cannabis company's regulatory issues.

Zynerba Pharma Looks Like Bad Medicine for Investors

Zynerba Pharma Looks Like Bad Medicine for Investors

The charts make ZYNE look bearish and not particularly attractive, so avoid.

Big Victory for the Bulls: Cramer's 'Mad Money' Recap (Monday 7/22/19)

Big Victory for the Bulls: Cramer's 'Mad Money' Recap (Monday 7/22/19)

Jim Cramer says that in the heart of earnings season, Wall Street analysts can make important calls that let bulls push stocks higher.

Berkshire Hathaway, Seattle Genetics, Zynerba: 'Mad Money' Lightning Round

Berkshire Hathaway, Seattle Genetics, Zynerba: 'Mad Money' Lightning Round

Jim Cramer takes a look at Berkshire Hathaway, Seattle Genetics, Zynerba Pharmaceuticals, Range Resources, Guardant Health, Danaher and more.

WATCH for Scale: Cramer's 'Mad Money' Recap (Thursday 7/11/19)

WATCH for Scale: Cramer's 'Mad Money' Recap (Thursday 7/11/19)

Jim Cramer highlights companies that can grow so big they make their own destinies: Walmart, Amazon, Target, Costco and Home Depot.

Don't You Dare Say 'Bubble': Cramer's 'Mad Money' Recap (Wednesday 7/10/19)

Don't You Dare Say 'Bubble': Cramer's 'Mad Money' Recap (Wednesday 7/10/19)

Jim Cramer says save the bubble-talk for the bathtub. The money investors can make in the market is real, and due to ingenuity, competitiveness and economic growth.

Planet Fitness, Allergan, Amarin: 'Mad Money' Lightning Round

Planet Fitness, Allergan, Amarin: 'Mad Money' Lightning Round

Jim Cramer weighs in on Planet Fitness, Allergan, Amarin, MPLX, Zynerba Pharmaceuticals, Schnieder National, United Parcel Service and more.

What's the Difference Between Indica vs. Sativa?

What's the Difference Between Indica vs. Sativa?

Indica and sativa are commonly-known distinctions among cannabis enthusiasts. But is there actually a distinct difference between the two? What roles do cannabinoids and terpenes play?

5 Cannabis ETFs to Fire Up Your Portfolio

5 Cannabis ETFs to Fire Up Your Portfolio

Two of them are brand new.

Ben & Jerry's Wants to Get in on CBD Craze

Ben & Jerry's Wants to Get in on CBD Craze

The company's announcement comes ahead of an FDA's public hearing on the legalization of CBD-infused foods and beverages on Friday.

In the Crosshairs of the Trade War: Cramer's 'Mad Money' Recap (Tuesday 5/21/19)

In the Crosshairs of the Trade War: Cramer's 'Mad Money' Recap (Tuesday 5/21/19)

Jim Cramer reviews stocks poised to profit, and those at risk -- until we get some sign of a truce in the trade war.

Regeneron Stock Could Fall 13% to 52-Week Lows

Regeneron Stock Could Fall 13% to 52-Week Lows

Regeneron stock is under pressure after missing on earnings and revenue expectations. Are new lows on tap?